By Helgi Library - June 23, 2021
PHARMOS employed 441 employees in 2019, down 9.82% compared to the previous year. Historically, between 2006 and 2019, ...
By Helgi Library - June 23, 2021
PHARMOS employed 441 employees in 2019, down 9.82% compared to the previous year. Historically, between 2006 and 2019, ...
By Helgi Library - June 23, 2021
PHARMOS made a net profit of CZK 11.2 mil with revenues of CZK 10,337 mil in 2019, up by 128% and up by 1.62%, respec...
| Profit Statement |
| Balance Sheet |
| Ratios |
| Cash Flow |
Get all company financials in excel:
Get all company financials in excel:
By Helgi Library - June 23, 2021
PHARMOS made a net profit of CZK 11.2 mil with revenues of CZK 10,337 mil in 2019, up by 128% and up by 1.62%, respectively, compared to the previous year. This translates into a net margin of 0.108%. On the operating level, EBITDA reached CZK 57.5 mil, ...
By Helgi Library - June 23, 2021
PHARMOS made a net profit of CZK 11.2 mil with revenues of CZK 10,337 mil in 2019, up by 128% and up by 1.62%, respectively, compared to the previous year. This translates into a net margin of 0.108%. Historically, between 2006 and 2019, the firm’...
By Helgi Library - June 23, 2021
PHARMOS made a net profit of CZK 11.2 mil with revenues of CZK 10,337 mil in 2019, up by 128% and up by 1.62%, respectively, compared to the previous year. This translates into a net margin of 0.108%. Historically, between 2006 and 2019, the firm’...
By Helgi Library - June 23, 2021
PHARMOS's total assets reached CZK 3,460 mil at the end of 2019, down 0.661% compared to the previous year. Current assets amounted to CZK 3,099 mil, or 89.6% of total assets while cash stood at CZK 51.9 mil at the end of 2019. ...
By Helgi Library - June 23, 2021
PHARMOS's total assets reached CZK 3,460 mil at the end of 2019, down 0.661% compared to the previous year. Current assets amounted to CZK 3,099 mil, or 89.6% of total assets while cash stood at CZK 51.9 mil at the end of 2019. ...
By Helgi Library - June 23, 2021
PHARMOS's operating cash flow stood at CZK 7.52 mil in 2019, down 95.7% when compared to the previous year. Historically, between 2006 - 2019, the firm’s operating cash flow reached a high of CZK 177 mil in 2018 and a low of CZK -147 mil in 2013. ...
By Helgi Library - June 23, 2021
PHARMOS's operating cash flow stood at CZK 7.52 mil in 2019, down 95.7% when compared to the previous year. Historically, between 2006 - 2019, the firm’s operating cash flow reached a high of CZK 177 mil in 2018 and a low of CZK -147 mil in 2013. ...
By Helgi Library - June 23, 2021
PHARMOS made a net profit of CZK 11.2 mil in 2019, up 128% compared to the previous year. Historically, between 2006 and 2019, the company's net profit reached a high of CZK 44.3 mil in 2016 and a low of CZK -27.0 mil in 2012. The result implies a return ...
By Helgi Library - June 23, 2021
PHARMOS made a net profit of CZK 11.2 mil in 2019, up 128% compared to the previous year. Historically, between 2006 and 2019, the company's net profit reached a high of CZK 44.3 mil in 2016 and a low of CZK -27.0 mil in 2012. The result implies a return ...
By Helgi Library - June 23, 2021
PHARMOS's net debt stood at CZK 1,245 mil and accounted for 191% of equity at the end of 2019. The ratio is down 10.3 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 201% in 2018 and a low of 19...
PHARMOS, a.s. is a Czech Republic-based distributor of medications and pharmaceuticals to public and hospital pharmacies in Czech Republic. The company was founded in 1991 and is based in Ostrava, Czech Republic. PHARMOS, a.s. operates as a subsidiary of Ceska Lekarnicka.
PHARMOS has been growing its sales by -0.691% a year on average in the last 5 years. EBITDA has grown on average by 4.91% a year during that time to total of CZK 57.5 mil in 2019, or 0.556% of sales. That’s compared to 0.569% average margin seen in last five years.
The company netted CZK 11.2 mil in 2019 implying ROE of 1.72% and ROCE of 0.527%. Again, the average figures were 3.03% and 1.10%, respectively when looking at the previous 5 years.
PHARMOS’s net debt amounted to CZK 1,245 mil at the end of 2019, or 191% of equity. When compared to EBITDA, net debt was 21.7x, down when compared to average of 24.5x seen in the last 5 years.
Helgi Library 
